Back to top
more

Sinovac Biotech (SVA)

(Delayed Data from NSDQ)

$6.47 USD

6.47
NA

0.00 (0.00%)

Updated Feb 22, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for SVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Sinovac Biotech, Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents -99,999 11,321 13,426 1,185 206
Receivables NA 609 952 253 114
Notes Receivable NA 0 0 0 0
Inventories NA 181 376 106 28
Other Current Assets NA 15 161 16 2
Total Current Assets NA 12,126 14,915 1,560 350
Net Property & Equipment NA 994 903 200 74
Investments & Advances NA 661 656 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 71 52 27 11
Intangibles NA 10 1 1 0
Deposits & Other Assets NA 194 105 28 10
Total Assets NA 14,115 16,748 1,901 452
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 4 2 6 7
Accounts Payable NA 906 1,021 211 59
Current Portion Long-Term Debt NA 0 3 33 6
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 1,268 35 2
Other Current Liabilities NA 175 110 390 13
Total Current Liabilities NA 1,092 2,413 680 87
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 242 324 3 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 12 17 8 1
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 5 5 5 6
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,402 2,872 781 100
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 541 548 539 208
Retained Earnings NA 7,226 7,142 144 57
Other Equity NA 4,946 6,186 437 87
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 12,713 13,876 1,120 352
Total Liabilities & Shareholder's Equity NA 14,115 16,748 1,901 452
Total Common Equity 0 12,713 13,876 1,120 352
Shares Outstanding 99.50 99.50 99.50 99.30 98.90
Book Value Per Share 0.00 127.77 139.46 11.28 3.56

Fiscal Year End for Sinovac Biotech, Ltd falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,999 -99,999 11,073 -99,999
Receivables NA NA NA 500 NA
Notes Receivable NA NA NA NA NA
Inventories NA NA NA 183 NA
Other Current Assets NA NA NA 13 NA
Total Current Assets NA NA NA 11,769 NA
Net Property & Equipment NA NA NA 1,059 NA
Investments & Advances NA NA NA 658 NA
Other Non-Current Assets NA NA NA NA NA
Deferred Charges NA NA NA 99 NA
Intangibles NA NA NA 9 NA
Deposits & Other Assets NA NA NA 84 NA
Total Assets NA NA NA 13,725 NA
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA 4 NA
Accounts Payable NA NA NA 820 NA
Current Portion Long-Term Debt NA NA NA 201 NA
Current Portion Capital Leases NA NA NA NA NA
Accrued Expenses NA NA NA NA NA
Income Taxes Payable NA NA NA NA NA
Other Current Liabilities NA NA NA 159 NA
Total Current Liabilities NA NA NA 1,190 NA
Mortgages NA NA NA NA NA
Deferred Taxes/Income NA NA NA 239 NA
Convertible Debt NA NA NA NA NA
Long-Term Debt NA NA NA 11 NA
Non-Current Capital Leases NA NA NA NA NA
Other Non-Current Liabilities NA NA 7 NA
Minority Interest (Liabilities) NA NA NA NA NA
Total Liabilities NA NA NA 1,488 NA
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA 0 NA
Common Stock (Par) NA NA NA 0 NA
Capital Surplus NA NA NA 541 NA
Retained Earnings NA NA NA 7,240 NA
Other Equity NA NA NA 4,456 NA
Treasury Stock NA NA NA NA NA
Total Shareholder's Equity NA NA NA 12,237 NA
Total Liabilities & Shareholder's Equity NA NA NA 13,725 NA
Total Common Equity 0 0 0 12,237 0
Shares Outstanding NA 99.50 99.50 99.50 99.50
Book Value Per Share 0.00 0.00 0.00 122.99 0.00